TY - JOUR
T1 - Sympathetic activity in obesity
T2 - a brief review of methods and supportive data
AU - Lambert, Gavin W.
AU - Schlaich, Markus P.
AU - Eikelis, Nina
AU - Lambert, Elisabeth A.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - The increase in the prevalence of obesity and the concomitant rise in obesity-related illness have led to substantial pressure on health care systems throughout the world. While the combination of reduced exercise, increased sedentary time, poor diet, and genetic predisposition is undoubtedly pivotal in generating obesity and increasing disease risk, a large body of work indicates that the sympathetic nervous system (SNS) contributes to obesity-related disease development and progression. In obesity, sympathetic nervous activity is regionalized, with activity in some outflows being particularly sensitive to the obese state, whereas other outflows, or responses to stimuli, may be blunted, thereby making the assessment of sympathetic nervous activation in the clinical setting difficult. Isotope dilution methods and direct nerve recording techniques have been developed and utilized in clinical research, demonstrating that in obesity there is preferential activation of the muscle vasoconstrictor and renal sympathetic outflows. With weight loss, sympathetic activity is reduced. Importantly, sympathetic nervous activity is associated with end-organ dysfunction and changes in sympathetic activation that accompany weight loss are often reflected in an improvement of end-organ function. Whether targeting the SNS directly improves obesity-related illness remains unknown, but merits further attention.
AB - The increase in the prevalence of obesity and the concomitant rise in obesity-related illness have led to substantial pressure on health care systems throughout the world. While the combination of reduced exercise, increased sedentary time, poor diet, and genetic predisposition is undoubtedly pivotal in generating obesity and increasing disease risk, a large body of work indicates that the sympathetic nervous system (SNS) contributes to obesity-related disease development and progression. In obesity, sympathetic nervous activity is regionalized, with activity in some outflows being particularly sensitive to the obese state, whereas other outflows, or responses to stimuli, may be blunted, thereby making the assessment of sympathetic nervous activation in the clinical setting difficult. Isotope dilution methods and direct nerve recording techniques have been developed and utilized in clinical research, demonstrating that in obesity there is preferential activation of the muscle vasoconstrictor and renal sympathetic outflows. With weight loss, sympathetic activity is reduced. Importantly, sympathetic nervous activity is associated with end-organ dysfunction and changes in sympathetic activation that accompany weight loss are often reflected in an improvement of end-organ function. Whether targeting the SNS directly improves obesity-related illness remains unknown, but merits further attention.
KW - obesity
KW - metabolic syndrome
KW - norepinephrine
KW - microneurography
KW - POSITIVE AIRWAY PRESSURE
KW - HEART-RATE-VARIABILITY
KW - C-REACTIVE PROTEIN
KW - OBSTRUCTIVE SLEEP-APNEA
KW - NERVOUS-SYSTEM ACTIVITY
KW - DIETARY WEIGHT-LOSS
KW - BODY-MASS INDEX
KW - BLOOD-PRESSURE
KW - NORADRENALINE SPILLOVER
KW - PLASMA NOREPINEPHRINE
U2 - 10.1111/nyas.14140
DO - 10.1111/nyas.14140
M3 - Review article
C2 - 31268175
SN - 0077-8923
VL - 1454
SP - 56
EP - 67
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
IS - 1
ER -